SIGA Stock Recent News
SIGA LATEST HEADLINES
Monkeypox stocks, our topic for today, have had a mostly mixed performance so far in 2022. It is likely, however, that they could benefit from the similar tailwinds enjoyed by companies, such as Pfizer (NYSE: PFE ), BioNTech (NASDAQ: BNTX ), and Moderna (NASDAQ: MRNA ), which have developed the Covid-19 vaccines that have now become household names.
The beaten-down stock market has created an opportunity for contrarian investors in short-squeeze stocks. Essentially, bearish traders must borrow the underlying securities which they are pessimistic about.
In a year where investing in stocks was more challenging than usual, finding winning stocks has been tough.
There's a lot going on with Siga Technologies (NASDAQ: SIGA ) stock lately. First of all, Siga released its second-quarter 2022 financial results.
The monkeypox outbreak has sent the drugmaker's stock up more than 200% this year, though its antiviral remains hard to access in the U.S.
SIGA Technologies, Inc. (NASDAQ:SIGA ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Phillip Gomez - CEO & Director Dennis Hruby - EVP & Chief Scientific Officer Daniel Luckshire - EVP, CFO & Secretary Conference Call Participants Soo Romanoff - Edison Group Peter Imber - North Point Partners Operator Welcome to the SIGA business update call. Before we turn the call over to SIGA management, please note that any forward-looking statements made during this call are based on management's current expectations and observations and are subject to risks and uncertainties that could cause actual results to differ from the forward-looking statements.
The stock skyrocketed last month.
10 monkeypox stocks and monkeypox penny stocks to watch The post 10 Top Monkeypox Stocks To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Should investors be watching these monkeypox stocks right now?
After the FDA provided an update on the agency's response to the monkeypox outbreak on July 29th, investors misunderstood the FDA's statements, and the stock sold off 33% and shortly reverted. SIGA's monkeypox treatment TPOXX is already approved in the U.S., EU, and Canada for smallpox and/or monkeypox, further de-risking the equity story.